Title : Differential sensitivity of renal carcinoma cells to doxorubicin and epigenetic therapeutics depends on the genetic background.

Pub. Date : 2021 Jun

PMID : 33591455






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Important findings of this study suggest that doxorubicin is more cytotoxic to primary renal cancer 786-0 cells with mutant VHL and p53 than the metastatic Caki-1 cells with wild-type VHL and p53, and this differential response was independent of p53 expression level. Doxorubicin tumor protein p53 Homo sapiens
2 This study suggests that combination of doxorubicin with epigenetic therapeutics could potentially be beneficial in clinical treatment of renal cancer patients with wild-type VHL and p53 but not in patients with mutant VHL and p53. Doxorubicin tumor protein p53 Homo sapiens